A proposed Hodgkin's lymphoma treatment returned positive test results in a clinical trial, according to drugmaker Seattle Genetics Inc. (SGEN), which seeks to file the drug for approval with the U.S. Food and Drug Administration next year.
The drug, called brentuximab vedotin, shrank tumors in three-quarters of the 102 Hodgkin's lymphoma patients tested, Seattle Genetics Inc. said in a statement today. Patients were tested for longer than six months on average, according to the company.
Hodgkin's disease kills 1,300 of the 8,500 Americans it strikes each year, according to the New York Times. About three-quarters of the affected adults may be cured with radiation or chemotherapy, the Times said, citing the National Cancer Institute.
Seattle Genetics narrowed its second-quarter loss to $8.32 million from $22.5 million a year earlier after more than tripling revenue to $36.9 million on its collaboration with Roche Group unit Genentech on the dacetuzumab treatment for non-Hodgkin's lymphoma.